51³ΙΘΛΆ―Βώ

Meeting Coverage

ASH Video Pearls: Multiple Myeloma

Multiple Myeloma Video Pearls from the American Society of Hematology

Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma

Subcutaneous administration of the anti-CD38 antibody also made for easier dosing

image

Latest ASH Video Pearls: Multiple Myeloma Meeting Coverage

Lower Blenrep Dose More Feasible With Revlimid in Myeloma, Early Trial Suggests

Less-intense belantamab mafodotin schedule proved more tolerable in combination regimen

December 28, 2023
Can JAK Inhibition Help Overcome Lenalidomide Resistance in Myeloma?

Early-phase experience with ruxolitinib suggests potential role in relapsed/refractory disease

December 21, 2023
Why Some Myeloma Patients Refuse Stem Cell Transplant

Study shows the various factors behind refusal of autologous stem cell transplantation

December 15, 2023
Is PFS Benefit Enough to Support Upfront Transplant in Multiple Myeloma?

DETERMINATION asks if we are doing more than necessary for transplant-eligible patients

January 11, 2023
Microenvironment May Predict Sustained MRD Negativity in Newly Diagnosed Myeloma

Eileen Boyle, MD, PhD, discusses research to identify determinants of deep response to dara-KRd

January 4, 2023
How Long Should Myeloma Patients Continue Lenalidomide After AutoSCT?

Gareth Morgan, MD, PhD describes the takeaways from the Myeloma XI Trial

December 28, 2022
Elranatamab Active in Relapsed or Refractory Multiple Myeloma

Noopur Raje, MD, discusses the results of the MagnetisMM-1 trial

December 21, 2022
D-Rd for Newly Diagnosed Myeloma Patients With Poor Kidney Function

Saad Usmani, MD, discusses follow-up results from the phase III MAIA study

January 23, 2022
'Very Promising': Daratumumab as Part of Multiple Myeloma Care

Ken Shain, MD, discusses the updated analysis of GRIFFIN

December 17, 2020

Latest Oncology/Hematology Meeting Coverage